Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 1Suspended 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 7Thoracic 3Gynecologic 3Dermatologic 3Sarcoma 2Genitourinary 2Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Melanoma 137Skin Neoplasms 21Neoplasm Metastasis 19Carcinoma, Renal Cell 16Kidney Neoplasms 15Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Sezary Syndrome 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasms 3Urinary Bladder Neoplasms 2Testicular Neoplasms 2Testicular Germ Cell Tumor 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Melanoma, Experimental 2Lymphoma, Non-Hodgkin 2

Interventions

pembrolizumab 28Nivolumab 14Ipilimumab 7Cyclophosphamide 7spartalizumab 6atezolizumab 4Interleukin-2 4fludarabine 3durvalumab 3cemiplimab 3avelumab 3aldesleukin 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Immune Checkpoint Inhibitors 3Docetaxel 3obinutuzumab 2epacadostat 2budigalimab 2bempegaldesleukin 2Pemetrexed 2Paclitaxel 2Leucovorin 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2vocimagene amiretrorepvec 1venetoclax 1utomilumab 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × aldesleukin × Dermatologic × Clear all
NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Hadassah Medical Organization

Phase 1/2 Recruiting
3 enrolled
BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT04551885 2023-09-21

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
12 enrolled
BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03970382 2022-08-18

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

PACT Pharma, Inc.

Phase 1 Suspended
21 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡